Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

81. The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial (PubMed)

The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial To investigate the effectiveness of exercise as treatment for vasomotor menopausal symptoms.Three-group randomised controlled trial, two exercise interventions and a control group.Primary Care, West Midlands UK.Perimenopausal and postmenopausal women experiencing at least five hot flushes/night sweats per day and not taken MHT in previous 3 months were recruited from 23 general (...) practices.Participants in both exercise interventions groups were offered two face-to-face consultations with a physical activity facilitator to support engagement in regular exercise. In addition, one exercise group received a menopause-specific information DVD and written materials to encourage regular exercise and the other exercise group was offered the opportunity to attend exercise social support groups in their communities. Interventions lasted 6 months.The primary outcome was frequency of hot flushes/night

Full Text available with Trip Pro

2015 EvidenceUpdates

82. Dehydroepiandrosterone for the Treatment of Menopausal or Andropausal Symptoms

Dehydroepiandrosterone for the Treatment of Menopausal or Andropausal Symptoms Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should (...) of Menopausal or Andropausal Symptoms: Clinical Effectiveness and Safety DATE: 25 February 2015 RESEARCH QUESTION What is the clinical effectiveness and safety of dehydroepiandosterone (DHEA) for the treatment of menopausal or andropausal symptoms? KEY FINDINGS Two systematic reviews, two randomized controlled trials, and one non-randomized study were identified regarding the clinical effectiveness and safety of DHEA for the treatment of menopausal symptoms; no evidence was identified regarding DHEA

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

83. Menopause

Menopause Menopause - NICE CKS Clinical Knowledge Summaries Share Menopause: Summary Menopause is a biological stage in a woman's life when menstruation ceases permanently due to the loss of ovarian follicular activity. It occurs with the final menstrual period and is usually diagnosed clinically after 12 months of amenorrhoea. In the UK, the mean age of the natural menopause is 51 years, although this can vary between different ethnic groups. Perimenopause is the period before the menopause (...) when the endocrinological, biological, and clinical features of approaching menopause commence. It is characterized by irregular cycles of ovulation and menstruation and ends 12 months after the last menstrual period. Postmenopause is the time after a woman has not had a period for 12 consecutive months. Premature menopause is usually defined as menopause occurring before the age of 40 years. Alterations in hormonal levels result in menopausal symptoms. Vasomotor symptoms (hot flushes and night

2015 NICE Clinical Knowledge Summaries

84. Treatment of Symptoms of the Menopause

Treatment of Symptoms of the Menopause '); '); Treatment of the Symptoms of Menopause Guideline Resources | Endocrine Society Hormone Science to Health / › › › Guidelines and Clinical Practice Section + Full Guideline: JCEM | November 2015 Cynthia A. Stuenkel (chair), Susan R. Davis, Anne Gompel, Mary Ann Lumsden, M. Hassan Murad, JoAnn V. Pinkerton, and Richard J. Santen The 2015 guideline addresses: General evaluation and health considerations for menopausal women Evaluating hormone (...) replacement options and associated risks Monitoring patients during hormone therapies Treating genitourinary syndrome Resources | ENDO 2015 | Guideline Central | Hormone Health Network | Endocrine Society Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline | ENDO 2015 Essential Points The Endocrine Society recommends that women with a uterus who decide to undergo menopausal hormone therapy with estrogen and progestogen be informed about risks and benefits, including

2015 The Endocrine Society

85. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society

Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society Copyright @ 2015 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. POSITION STATEMENT Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society Abstract Objective: To update and expand The North American Menopause Society’s evidence-based position (...) on nonhormonal management of menopause-associated vasomotor symptoms (VMS), previously a portion of the position statement on the management of VMS. Methods: NAMS enlisted clinical and research experts in the field and a reference librarian to identify and review available evidence. Five different electronic search engines were used to cull relevant literature. Using the literature, experts created a document for final approval by the NAMS Board of Trustees. Results: Nonhormonal management of VMS

2015 The North American Menopause Society

86. Menopause: diagnosis and management

Menopause: diagnosis and management Menopause: diagnosis and management Menopause: diagnosis and management NICE guideline Published: 12 November 2015 nice.org.uk/guidance/ng23 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Menopause: diagnosis and management (NG23) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 30Contents Contents Overview 4 Who is it for? 4 Recommendations 5 1.1 Individualised care 5 1.2 Diagnosis

2015 National Institute for Health and Clinical Excellence - Clinical Guidelines

87. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review (PubMed)

Vaginal estrogen for genitourinary syndrome of menopause: a systematic review To comprehensively review and critically assess the literature on vaginal estrogen and its alternatives for women with genitourinary syndrome of menopause and to provide clinical practice guidelines.MEDLINE and Cochrane databases were searched from inception to April 2013. We included randomized controlled trials and prospective comparative studies. Interventions and comparators included all commercially available

Full Text available with Trip Pro

2015 EvidenceUpdates

88. Exercise for vasomotor menopausal symptoms. (PubMed)

Exercise for vasomotor menopausal symptoms. Evidence suggests that many perimenopausal and early postmenopausal women will experience menopausal symptoms; hot flushes are the most common. Symptoms caused by fluctuating levels of oestrogen may be alleviated by hormone therapy (HT), but a marked global decline in its use has resulted from concerns about the risks and benefits of HT. Consequently, many women are seeking alternatives. As large numbers of women are choosing not to take HT (...) , it is increasingly important to identify evidence-based lifestyle modifications that have the potential to reduce vasomotor menopausal symptoms.To examine the effectiveness of any type of exercise intervention in the management of vasomotor symptoms in symptomatic perimenopausal and postmenopausal women.Searches of the following electronic bibliographic databases were performed to identify randomised controlled trials (RCTs): Cochrane Menstrual Disorders and Subfertility Group Specialised Trials Register

Full Text available with Trip Pro

2014 Cochrane

89. Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women ? first line in combination with letrozole

Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women ? first line in combination with letrozole Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women – first line in combination with letrozole Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women – first line in combination with letrozole NIHR HSC Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women – first line in combination with letrozole. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents; Breast Neoplasms; Female; Humans Language Published English

2014 Health Technology Assessment (HTA) Database.

90. Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women

Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women Denosumab versus bifosfonatos para el tratamiento de la osteoporosis en mujeres post menopáusicas [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Denosumab versus bifosfonatos para el tratamiento de la osteoporosis en mujeres post menopáusicas [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Pichon Riviere (...) en mujeres post menopáusicas. [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N° 308. 2013 Authors' objectives To assess the available evidence on the efficacy, safety and coverage policy related aspect for denosumab versus bisphosphonates in decreasing the risk of fractures due to post-menopausal osteoporosis. Authors' conclusions

2014 Health Technology Assessment (HTA) Database.

91. Management of Menopausal Symptoms

Management of Menopausal Symptoms Sign In (ACOG) Sign in to your ACOG account Email is required. Please enter valid Email. was not found in our system. Would you like to associated with your account? Forgot your email address? JSOG Member? © 2019 - American College of Obstetricians and Gynecologists

2014 American College of Obstetricians and Gynecologists

92. Osteoporosis in Menopause

Osteoporosis in Menopause Osteoporosis in Menopause - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Pages 839–840 Osteoporosis in Menopause PRINCIPAL AUTHORS, x Aliya Khan , MD Hamilton ON x Michel Fortier , MD Quebec QC x MENOPAUSE AND OSTEOPOROSIS WORKING GROUP x Michel Fortier , MD (Co-Chair) x Michel Fortier , x Robert Reid , MD (Co-Chair) x Robert Reid , x Beth L. Abramson , MD x Beth L. Abramson , x (...) osteoporosis. Evidence Published literature was retrieved through searches of PubMed and The Cochrane Library on August 30 and September 18, 2012, respectively. The strategy included the use of appropriate controlled vocabulary (e.g., oteoporosis, bone density, menopause) and key words (e.g., bone health, bone loss, BMD). Results were restricted to systematic reviews, practice guidelines, randomized and controlled clinical trials, and observational studies published in English or French. The search

2014 Society of Obstetricians and Gynaecologists of Canada

93. Managing Menopause Chapter 9 Complementary and Alternative Medicine (CAM)

Managing Menopause Chapter 9 Complementary and Alternative Medicine (CAM) Managing Menopause Chapter 9 Complementary and Alternative Medicine (CAM) - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S74–S80 Managing Menopause Chapter 9 Complementary and Alternative Medicine (CAM) DOI: To view the full text, please login as a subscribed user or . Click to view the full text

2014 Society of Obstetricians and Gynaecologists of Canada

94. Managing Menopause Chapter 7 Ongoing Management of Menopausal Women and Those With Special Considerations

Managing Menopause Chapter 7 Ongoing Management of Menopausal Women and Those With Special Considerations Managing Menopause Chapter 7 Ongoing Management of Menopausal Women and Those With Special Considerations - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S51–S58 Managing Menopause Chapter 7 Ongoing Management of Menopausal Women and Those With Special Considerations DOI: To view (...) the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Figures Figure 7.1 The Stages of Reproductive Aging Workshop + 10 staging system for reproductive aging in women The goal of this chapter is to give practical tips to health care providers for the management of symptomatic women during and after the menopausal transition, concerning mostly the initiation and follow-up of HT. The reader may refer to previous chapters for more extensive literature review

2014 Society of Obstetricians and Gynaecologists of Canada

95. Managing Menopause Chapter 2 Cardiovascular Disease

Managing Menopause Chapter 2 Cardiovascular Disease Managing Menopause Chapter 2 Cardiovascular Disease - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S16–S22 Managing Menopause Chapter 2 Cardiovascular Disease DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Consensus is emerging from the controversy and confusion (...) that has occupied the past decade regarding the effects of postmenopausal HT on CVD. Since the publication of the SOGC’s Canadian Consensus Conference on Menopause in 2006, 1 several publications have shed additional light on this subject. To access this article, please choose from the options below Log In Register Purchase access to this article Claim Access If you are a current subscriber with Society Membership or an Account Number, . Subscribe to this title to gain access to this and all other

2014 Society of Obstetricians and Gynaecologists of Canada

96. Managing Menopause Chapter 4 Vasomotor Symptoms

Managing Menopause Chapter 4 Vasomotor Symptoms Managing Menopause Chapter 4 Vasomotor Symptoms - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S31–S34 Managing Menopause Chapter 4 Vasomotor Symptoms DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. VMS affect 60% to 80% of women entering menopause. 1 Hot flashes are common (...) in the perimenopausal transition, when ovarian activity may be intermittent, and they have also been documented during the luteal and menstrual phases of the cycle in women with premenstrual dysphoric disorder. 2 After menopause, it is important to be alert to atypical features or to a lack of response to effective therapy, which might indicate an alternative cause of the symptoms. The differential diagnosis includes hyperthyroidism, anxiety, panic attack, hypertension, emotional flushing, neurologic flushing

2014 Society of Obstetricians and Gynaecologists of Canada

97. Managing Menopause Chapter 1 Assessment and Risk Management of Menopausal Women

Managing Menopause Chapter 1 Assessment and Risk Management of Menopausal Women Managing Menopause Chapter 1 Assessment and Risk Management of Menopausal Women - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S6–S15 Managing Menopause Chapter 1 Assessment and Risk Management of Menopausal Women DOI: To view the full text, please login as a subscribed user or . Click to view the full (...) text on ScienceDirect. Figures Menopause is an important milestone and may be one of the first times a woman seeks medical advice around issues of long-term health promotion and disease prevention. Women typically begin to experience menopausal symptoms between 40 and 58 years of age, spending at least one third of their lives after menopause. 1 The 3 main causes of illness and disability in developed countries for postmenopausal women are CVD, cancer, and osteoporosis-associated fractures. 2

2014 Society of Obstetricians and Gynaecologists of Canada

98. Managing Menopause Abstract and Summary Statement

Managing Menopause Abstract and Summary Statement Managing Menopause Abstract and Summary Statement - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S1–S5 Managing Menopause Abstract and Summary Statement PRINCIPAL AUTHORS, x Robert Reid , MD Kingston ON x Beth L. Abramson , MD Toronto ON x Jennifer Blake , MD Toronto ON x Sophie Desindes , MD Sherbrooke QC x Sylvie Dodin , MD Quebec QC (...) x Shawna Johnston , MD Kingston ON x Timothy Rowe , MB BS Vancouver BC x Namrita Sodhi , MD Toronto ON x Penny Wilks , ND Dundas ON x Wendy Wolfman , MD Toronto ON x MENOPAUSE AND OSTEOPOROSIS WORKING GROUP x Michel Fortier , MD (Co-Chair) x Michel Fortier , x Robert Reid , MD (Co-Chair) x Robert Reid , x Beth L. Abramson , MD x Beth L. Abramson , x Jennifer Blake , MD x Jennifer Blake , x Sophie Desindes , MD x Sophie Desindes , x Sylvie Dodin , MD x Sylvie Dodin , x Lisa Graves , MD x Lisa

2014 Society of Obstetricians and Gynaecologists of Canada

99. Managing Menopause Chapter 5 Urogenital Health

Managing Menopause Chapter 5 Urogenital Health Managing Menopause Chapter 5 Urogenital Health - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S35–S41 Managing Menopause Chapter 5 Urogenital Health DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. The vagina, lower urinary tract, and pelvic floor have the same embryologic (...) origin, and therefore all contain estrogen receptors and undergo atrophy in the estrogen-deficient state of menopause. The concept of urogenital aging encompasses the altered structure and function of the urogenital tissues under the combined influence of estrogen loss from menopause and tissue aging. Although tissue aging is both insidious and inevitable, the effect of estrogen loss on the urogenital tissues is relatively rapid and, at least to some extent, reversible with ET. To access this article

2014 Society of Obstetricians and Gynaecologists of Canada

100. Managing Menopause Chapter 6 Prescription Therapeutic Agents

Managing Menopause Chapter 6 Prescription Therapeutic Agents Managing Menopause Chapter 6 Prescription Therapeutic Agents - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S42–S50 Managing Menopause Chapter 6 Prescription Therapeutic Agents DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. In November 1929, clinicians

2014 Society of Obstetricians and Gynaecologists of Canada